Valuation
- Market cap
- 1,000
- Revenue TTM
- $0
- Net income TTM
- $-35,810,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 22.80
Trading
- Volume
- 300
- Avg volume
- 5,130
- Day's range
- $0.00 – $0.00
- Shares out
- 4,704,000
- Stochastic %K
- 0%
- Beta
- 2.73
- Analysts
- Strong Buy
- Price target
- $10.00
Company profile
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat p...
Show more
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 925 8215
- Website
- https://effector.com
- Address
- 142 North Cedros Avenue, Suite B, Solana Beach, United States
Latest news
No headlines yet.
Stocktwits
11thestate
Jul 10, 8:11 PM
$EFTR investors: eFFECTOR Therapeutics is being investigated over claims that it failed to disclose risks before shutting down operations.
If you held
$EFTR shares, you can join the investigation so you don’t miss any updates or potential recovery: https://11th.com/cases/effector-investor-case
0 replies
PenkeInvesting
Jun 23, 6:58 PM
Fundamental analysis of
$EFTR (eFFECTOR Therapeutics, Inc.) based on financial data and reported results. #EFTR #eFFECTOR
Golibajje
Feb 13, 2:34 PM
$LYRA There is a reason why Sabby entered with 9.90% long position to short right after that corporate update! and it’s definitely not for good reason! Reminds me of cash rich
$EFTR which was taken to 0 by the mgmt by spending all the cash!
$LYRA mgmt seems to have similar intention!
1 replies
ZoeWeston5
Aug 26, 3:39 PM
$EFTR Today’s setup looks strong. Stay disciplined. Focus on the process. Expect positive outcomes. Keep sharp and aim for success!
0 replies
11thestate
May 30, 1:20 PM
$EFTR stockholders filed a claim against eFFECTOR Therapeutics for allegedly misleading investors ahead of its 2024 stock offering and abruptly announcing a full wind-down months later.
You can join this case to be notified about any new information: https://11th.com/cases/effector-investor-case
0 replies
11thestate
May 15, 12:08 PM
$EFTR stockholders filed a claim against eFFECTOR Therapeutics for misleading them about its clinical progress, financial stability, and future operations ahead of its 2024 stock offering.
You can join this case to be notified about potential recovery: https://11th.com/cases/effector-investor-case
0 replies
